CONCORD HC GP's Guangzhou Proton Center Treats Over 880 Patients in 18 Months, Daily Treatments Exceed 100

Stock News05-27

CONCORD HC GP (02453) announced that as of May 2026, its subsidiary Guangzhou Concord Cancer Hospital's Proton Therapy Center has been operational for 18 months. The center has cumulatively served over 880 patients, with daily treatments surpassing 100 patients. This milestone signifies a new level of precision radiotherapy capability for cancer treatment in South China. Patient services have extended across 31 provincial-level administrative regions in China and over 20 countries worldwide, with patients ranging in age from 13 months to 91 years. The treatment scope covers various malignant tumors, including pediatric cancers, central nervous system tumors, head and neck cancers (such as nasopharyngeal carcinoma), thoracic cancers (such as lung cancer and esophageal cancer), breast cancer, abdominal cancers (such as liver cancer), urological cancers (such as prostate cancer), and soft tissue sarcomas. Moving forward, the company will continue to optimize service processes and enhance diagnostic and treatment efficiency, dedicated to providing high-quality, precise proton therapy services to more cancer patients.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1117000947?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-27 19:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117000947","market":"us","top_or_hot":-1,"title":"CONCORD HC GP's Guangzhou Proton Center Treats Over 880 Patients in 18 Months, Daily Treatments Exceed 100","media":"Stock News","content":"<p>CONCORD HC GP (02453) announced that as of May 2026, its subsidiary Guangzhou Concord Cancer Hospital's Proton Therapy Center has been operational for 18 months. The center has cumulatively served over 880 patients, with daily treatments surpassing 100 patients. This milestone signifies a new level of precision radiotherapy capability for cancer treatment in South China. Patient services have extended across 31 provincial-level administrative regions in China and over 20 countries worldwide, with patients ranging in age from 13 months to 91 years. The treatment scope covers various malignant tumors, including pediatric cancers, central nervous system tumors, head and neck cancers (such as nasopharyngeal carcinoma), thoracic cancers (such as lung cancer and esophageal cancer), breast cancer, abdominal cancers (such as liver cancer), urological cancers (such as prostate cancer), and soft tissue sarcomas. Moving forward, the company will continue to optimize service processes and enhance diagnostic and treatment efficiency, dedicated to providing high-quality, precise proton therapy services to more cancer patients.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CONCORD HC GP's Guangzhou Proton Center Treats Over 880 Patients in 18 Months, Daily Treatments Exceed 100</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCONCORD HC GP's Guangzhou Proton Center Treats Over 880 Patients in 18 Months, Daily Treatments Exceed 100\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-27 19:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CONCORD HC GP (02453) announced that as of May 2026, its subsidiary Guangzhou Concord Cancer Hospital's Proton Therapy Center has been operational for 18 months. The center has cumulatively served over 880 patients, with daily treatments surpassing 100 patients. This milestone signifies a new level of precision radiotherapy capability for cancer treatment in South China. Patient services have extended across 31 provincial-level administrative regions in China and over 20 countries worldwide, with patients ranging in age from 13 months to 91 years. The treatment scope covers various malignant tumors, including pediatric cancers, central nervous system tumors, head and neck cancers (such as nasopharyngeal carcinoma), thoracic cancers (such as lung cancer and esophageal cancer), breast cancer, abdominal cancers (such as liver cancer), urological cancers (such as prostate cancer), and soft tissue sarcomas. Moving forward, the company will continue to optimize service processes and enhance diagnostic and treatment efficiency, dedicated to providing high-quality, precise proton therapy services to more cancer patients.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1209","symbol_name":"保健护理机构","start_time":0,"source_url":"","article_id":"1117000947","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117000947","pubTimestamp":1779882437,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CONCORD HC GP (02453) announced that as of May 2026, its subsidiary Guangzhou Concord Cancer Hospital's Proton Therapy Center has been operational for 18 months. The center has cumulatively served...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1209":"保健护理机构","02453":"美中嘉和"},"translate_title":"协和慧聪全科广州宝腾中心18个月收治患者超880人次，日治疗量超100人次","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02453":1},"content_text":"CONCORD HC GP (02453) announced that as of May 2026, its subsidiary Guangzhou Concord Cancer Hospital's Proton Therapy Center has been operational for 18 months. The center has cumulatively served over 880 patients, with daily treatments surpassing 100 patients. This milestone signifies a new level of precision radiotherapy capability for cancer treatment in South China. Patient services have extended across 31 provincial-level administrative regions in China and over 20 countries worldwide, with patients ranging in age from 13 months to 91 years. The treatment scope covers various malignant tumors, including pediatric cancers, central nervous system tumors, head and neck cancers (such as nasopharyngeal carcinoma), thoracic cancers (such as lung cancer and esophageal cancer), breast cancer, abdominal cancers (such as liver cancer), urological cancers (such as prostate cancer), and soft tissue sarcomas. Moving forward, the company will continue to optimize service processes and enhance diagnostic and treatment efficiency, dedicated to providing high-quality, precise proton therapy services to more cancer patients.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1117000947","isCrawlerRequest":true}